TD Cowen Raises Genmab A (GMAB) Price Target to $52
Key Points
- TD Cowen increased its price target for Genmab A to $52, up from $43, as of October 26, 2026.
- TD Cowen's $52 price target implies 16.10% upside from Genmab A's ($GMAB) current $44.79 share price.
- As of October 26, 2026, Genmab A shares traded recently around $44.79, slightly below the new target price.
- The company is scheduled to report its next earnings on November 5, 2026.
Get Genmab A text alerts
We text you when insiders, Congress, analysts or big funds move on $GMAB.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Genmab A alert may contain errors. Disclosures
On October 26, 2026, TD Cowen raised its price target on Genmab A (GMAB) to $52 from $43 while maintaining a Buy rating. This move comes as analysts show confidence in the company’s potential within the biotechnology sector.
GMAB
Genmab A
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
TD Cowen's Call on Genmab A
TD Cowen's new target price represents a notable increase, reflecting their positive outlook on Genmab’s performance. The stock closed at $44.82 on the same day, which places it slightly below the updated target. This suggests that analysts see room for growth in the stock price.
Other Institutional Activity in Genmab A
Several other institutional investors have also shown interest in Genmab A. Paradigm Biocapital Advisors LP holds 13,133,131 shares valued at about $588.6 million, having increased its holdings by 5,165,449 shares. Deerfield Management Company, L.P. owns 6,865,000 shares worth approximately $307.7 million, having added 4,403,015 shares. In contrast, Orbis Allan Gray Ltd reduced its stake by 1,557,548 shares, now holding 11,368,161 shares valued at about $509.5 million.
Genmab A Stock Up 12.0%
Genmab A's shares recently traded around $44.79, which is about equal to the closing price of $44.82 on October 26, 2026. The stock is trading significantly above its 52-week low of $23.62, reflecting a strong performance over the past year. It is also above its 50-day and 200-day moving averages by 27.2% and 49.0%, respectively, indicating bullish momentum.
$GMAB price target
Genmab A daily closes and this analyst's $52 target. Not advice.
Recent Earnings
Genmab A reported trailing twelve-month revenue of approximately $4.13 billion, with a year-over-year growth of 24.9%. The company's net margin stands at 19.1%, and its return on equity is 14.0%. The next earnings report is scheduled for November 5, 2026, which could provide further insights into its financial health.
Analysts Set New Price Targets
On the same day as TD Cowen's update, JP Morgan upgraded its rating on Genmab A to Overweight. Other firms like Truist Securities and Guggenheim maintained their Buy ratings, with price targets of $45.0 and $58.0, respectively, reflecting a consensus that remains optimistic about the stock’s potential.
About Genmab A
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focusing on developing antibody-based treatments for cancer and other diseases. The company markets several products, including EPKINLY and TEPKINLY for specific types of lymphoma and Tivdak for cervical cancer patients.
Bottom Line
Investors should watch for Genmab A's upcoming earnings report on November 5, 2026, as it may impact future analyst ratings and price targets. With TD Cowen’s recent price target adjustment, the market is keenly observing how the stock performs against these expectations.
Related Filing Alerts
Source: TD Cowen's rating change on $GMAB (Oct 26, 2026). Written by software, not financial advice. How we make alerts